Exagen Inc. (XGN)
USD 5.52
(-4.83%)
USD 5.52
(-4.83%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -23.68 Million USD | 50.01% |
| 2022 | -47.38 Million USD | -76.48% |
| 2021 | -26.85 Million USD | -60.91% |
| 2020 | -16.68 Million USD | -38.62% |
| 2019 | -12.03 Million USD | -50.25% |
| 2018 | -8.01 Million USD | 68.74% |
| 2017 | -25.63 Million USD | 0.0% |
| 2015 | -19.18 Million USD | -28.05% |
| 2014 | -14.98 Million USD | -11.0% |
| 2013 | -13.49 Million USD | -84.27% |
| 2012 | -7.32 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.96 Million USD | 11.73% |
| 2024 Q1 | -3.36 Million USD | 39.71% |
| 2023 Q1 | -8.3 Million USD | 42.12% |
| 2023 Q2 | -5.01 Million USD | 39.66% |
| 2023 Q4 | -5.57 Million USD | -2.92% |
| 2023 Q3 | -5.41 Million USD | -8.02% |
| 2023 FY | -23.68 Million USD | 50.01% |
| 2022 Q3 | -2.36 Million USD | 83.0% |
| 2022 Q4 | -14.35 Million USD | -506.93% |
| 2022 FY | -47.38 Million USD | -76.48% |
| 2022 Q1 | -10.86 Million USD | -54.05% |
| 2022 Q2 | -13.91 Million USD | -28.03% |
| 2021 Q4 | -7.05 Million USD | 1.76% |
| 2021 Q3 | -7.17 Million USD | -12.0% |
| 2021 Q2 | -6.41 Million USD | -3.24% |
| 2021 FY | -26.85 Million USD | -60.91% |
| 2021 Q1 | -6.2 Million USD | -79.81% |
| 2020 Q3 | -4.3 Million USD | -28.1% |
| 2020 FY | -16.68 Million USD | -38.62% |
| 2020 Q2 | -3.36 Million USD | 39.55% |
| 2020 Q4 | -3.45 Million USD | 19.85% |
| 2020 Q1 | -5.56 Million USD | -63.23% |
| 2019 Q3 | -3.14 Million USD | -12.78% |
| 2019 Q2 | -2.78 Million USD | -3.0% |
| 2019 Q1 | -2.7 Million USD | -105.32% |
| 2019 FY | -12.03 Million USD | -50.25% |
| 2019 Q4 | -3.4 Million USD | -8.5% |
| 2018 Q3 | -1.75 Million USD | 60.61% |
| 2018 Q4 | -1.31 Million USD | 25.0% |
| 2018 FY | -8.01 Million USD | 68.74% |
| 2018 Q2 | -4.45 Million USD | 16.31% |
| 2018 Q1 | -5.32 Million USD | 0.0% |
| 2017 FY | -25.63 Million USD | 0.0% |
| 2015 Q2 | -9.68 Million USD | -180.1% |
| 2015 Q4 | -2.53 Million USD | 27.75% |
| 2015 FY | -19.18 Million USD | -28.05% |
| 2015 Q1 | -3.45 Million USD | -32.54% |
| 2015 Q3 | -3.5 Million USD | 63.8% |
| 2014 Q1 | -3.56 Million USD | 44.76% |
| 2014 Q4 | -2.6 Million USD | 45.79% |
| 2014 Q3 | -4.81 Million USD | -20.57% |
| 2014 Q2 | -3.99 Million USD | -11.91% |
| 2014 FY | -14.98 Million USD | -11.0% |
| 2013 Q1 | -2.85 Million USD | 0.0% |
| 2013 FY | -13.49 Million USD | -84.27% |
| 2013 Q3 | -2.43 Million USD | 17.13% |
| 2013 Q2 | -2.93 Million USD | -2.91% |
| 2013 Q4 | -6.45 Million USD | -165.39% |
| 2012 FY | -7.32 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | 89.811% |
| Prenetics Global Limited | -62.72 Million USD | 62.233% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -1430.297% |
| CareDx, Inc | -190.28 Million USD | 87.551% |
| Exact Sciences Corporation | -204.14 Million USD | 88.396% |
| Inotiv, Inc. | -105.14 Million USD | 77.469% |
| Guardant Health, Inc. | -479.44 Million USD | 95.059% |
| Biodesix, Inc. | -52.14 Million USD | 54.572% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -801.05% |
| Precipio, Inc. | -5.85 Million USD | -304.733% |
| iSpecimen Inc. | -11.09 Million USD | -113.424% |
| Natera, Inc. | -434.8 Million USD | 94.552% |
| Aspira Women's Health Inc. | -16.69 Million USD | -41.935% |
| Standard BioTools Inc. | -74.65 Million USD | 68.269% |
| 23andMe Holding Co. | -666.7 Million USD | 96.447% |
| Castle Biosciences, Inc. | -57.46 Million USD | 58.777% |
| Personalis, Inc. | -108.29 Million USD | 78.126% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 73.227% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -138.151% |
| OpGen, Inc. | -32.66 Million USD | 27.487% |
| T2 Biosystems, Inc. | -50.07 Million USD | 52.695% |
| Myriad Genetics, Inc. | -112 Million USD | 78.849% |
| ICON Public Limited Company | 612.33 Million USD | 103.869% |
| NeoGenomics, Inc. | -87.96 Million USD | 73.071% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -1430.297% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 102.803% |
| RadNet, Inc. | 3.04 Million USD | 878.219% |
| MDxHealth SA | -43.1 Million USD | 45.037% |
| Psychemedics Corporation | -4.15 Million USD | -470.27% |
| Illumina, Inc. | -1.16 Billion USD | 97.96% |
| Check-Cap Ltd. | -17.56 Million USD | -34.842% |
| Twist Bioscience Corporation | -208.72 Million USD | 88.651% |
| DarioHealth Corp. | -59.42 Million USD | 60.138% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 85.885% |
| Sera Prognostics, Inc. | -36.24 Million USD | 34.637% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | -135.471% |
| OPKO Health, Inc. | -188.86 Million USD | 87.457% |
| Medpace Holdings, Inc. | 282.81 Million USD | 108.376% |
| Neogen Corporation | -9.42 Million USD | -151.449% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | -133.234% |
| Prenetics Global Limited | -62.72 Million USD | 62.233% |
| Mainz Biomed B.V. | -26.29 Million USD | 9.913% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -198.462% |
| Trinity Biotech plc | -24.01 Million USD | 1.37% |
| Neuronetics, Inc. | -30.18 Million USD | 21.531% |
| Sotera Health Company | 51.37 Million USD | 146.109% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -198.462% |